Becton Dickinson

Advanced Diagnostics And Tissue Regeneration Will Expand Decentralized Healthcare

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

18 Jul 24

Updated

07 Dec 25

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

-10.9%

7D

3.6%

Loading

1Y

-10.9%

7D

3.6%

You can edit this narrative until Dec 8 5:05 AM. Then, changes will post as Updates.

Author's Valuation

US$202.580.8% undervalued

AnalystConsensusTarget Fair Value

Shared on 07 Dec 25

Fair value Increased 0.54%

BDX: 2026 Separation And Reset Outlook Will Shape Returns Amid Headwinds

Analysts have modestly lowered their price target on Becton Dickinson to about $203 per share from roughly $201 previously. This reflects slightly higher long term revenue growth assumptions, offset by a marginally lower profit margin outlook and cautious views on FY26 guidance amid Alaris, China, and vaccine related headwinds.

Shared on 23 Nov 25

Fair value Decreased 2.46%

BDX: Modest Guidance and 2026 Separation Will Shape Future Performance Amid Headwinds

Becton Dickinson's analyst price target was reduced from approximately $206.58 to $201.49. Analysts attribute this change to cautious forward guidance, modest revenue expectations, and ongoing external headwinds highlighted in recent reports.

Shared on 07 Nov 25

Fair value Decreased 0.68%

BDX Will Unlock New Growth Following Planned 2026 Business Separation

Becton Dickinson Analyst Price Target Narrative Update The analyst fair value estimate for Becton Dickinson was reduced slightly from $208 to approximately $206.58, with analysts citing a more conservative earnings outlook and limited growth expectations in the near term. Analyst Commentary Analyst perspectives on Becton Dickinson reflect a balanced view of the company’s near-term challenges and long-term opportunities.

Shared on 07 May 25

Fair value Decreased 25%

Shared on 30 Apr 25

Fair value Increased 0.068%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 23 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 16 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 09 Apr 25

Fair value Decreased 0.55%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 02 Apr 25

Fair value Increased 1.36%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 26 Mar 25

Fair value Decreased 0.14%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 19 Mar 25

Fair value Increased 27%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 10 Mar 25

Fair value Increased 0.83%

AnalystConsensusTarget Fair Value

US$202.58

0.8% undervalued

Future estimation in

% p.a.

0

Decrease

Increase

Current revenue growth rate

2.91%

Medical Equipment revenue growth rate

8.48%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

%

0

Decrease

Increase

Current discount rate

8.47%

Calculation

US$2.79b

Earnings '28

x

25.98x

PE Ratio '28

=

US$72.47b

Market Cap '28

US$72.47b

Market Cap '28

/

280.33m

No. shares '28

=

US$258.51

Share Price '28

US$258.51 Share Price '28

Discounted to 2025 @ 8.51% p.a.

=

US$202.34

Fair Value '25